Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January
Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,300 shares, a decrease of 12.5% from the January 15th total of 7,200 shares. Based on an average daily volume of 14,600 shares, the short-interest ratio is currently 0.4 days.
奇魯達公司（NASDAQ：CELUW-獲取評級）是一月份短期利息顯著減少的目標。截至 1 月 31 日，總共有 6,300 股的短期利息，較 1 月 15 日共 7,200 股股份下降 12.5%。根據每日平均成交量為 14,600 股，短息比率目前為 0.4 天。
Celularity Price Performance
卓越性價格表現
Celularity stock remained flat at $0.10 during trading hours on Friday. Celularity has a 12-month low of $0.06 and a 12-month high of $1.99.
星期五交易時間內，精達股票保持平穩，為 0.10 美元。最高點為 12 個月低點 0.06 美元，12 個月高點為 1.99 美元。
Celularity Company Profile
卓達公司簡介
(Get Rating)
(取得評分)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc 是臨床階段的生物技術公司，開發現成的胎盤衍生異基因細胞療法，用於治療癌症，免疫和傳染病。它通過三個部分進行操作：細胞治療，退行性疾病和生物班王。該公司的主要治療方案包括 CYCART-19，胎盤衍生的 CAR-T 療法，該療法正在治療 B 細胞惡性腫瘤的 I 期臨床試驗中；CYNK-001，胎盤衍生的未修飾天然殺傷劑（NK）細胞，該細胞處於治療急性髓細胞白血病的 I 期臨床試驗中，以及用於治療急性髓細胞白血病的 I/IIA 期臨床試驗中，用於膠質瘤和 COVID-19 多形瘤治療試驗; CYNK-101 是一種異體轉基因 NK 細胞，正處於治療 HER2+ 胃癌和胃食管癌的 I 期臨床試驗中；APPL-001，胎盤-衍生的間充質樣附著劑基質細胞，處於治療克羅恩氏病的臨床前階段；和 PDA-002，胎盤衍生的間葉類粘附劑基質細胞，處於臨床前階段，用於治療面部異位素的肌肉營養不良。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- Deere Stock Raises Outlook and is Ready to Power Higher
- DraftKings Crowning Achievement: Leverage
- Tesla Stock Comeback Is Picking Up Steam
- How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
- 3 Top-Performing Energy MLPs Deliver Price Gains, High Yield
- 免費獲取有關天然性研究報告的副本
- 迪爾股票提高了前景，並準備提高動力
- 起草加冕成就：槓桿
- 特斯拉股票復出正在拿起蒸汽
- 雅培實驗室，艾伯維如何通過扣押藥物配方獲利
- 3 個效能最佳的能源 MLP 提供價格上漲、高收益
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日奇魯特的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Celularity 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。